Introduction
============

As the economy develops and vehicles become more and more common, the incidence of car accidents is constantly increasing, and that of traumatic brain injury (TBI) is also increasing. Severe traumatic brain injury (STBI) is an acute and severe disease that is common, with rapid progression and complicated conditions. After the patient is injured, there will be energy metabolism disturbance, hypoxia, apoptosis and massive release of oxygen free radicals in the body, which cause different necrosis and degeneration of the tissue ([@b1-etm-0-0-7503],[@b2-etm-0-0-7503]). Studies have shown that ([@b3-etm-0-0-7503],[@b4-etm-0-0-7503]) the progression of STBI is related to vascular permeability and inflammatory factor release. There is a study showing that ([@b5-etm-0-0-7503]) patients with STBI produce a large number of inflammatory mediators under long-term pathological stress, thereby leading the body into an inflammatory state and further aggravating the condition. Cerebrospinal fluid (CSF) is a rich medium in which inflammation is rapidly transmitted to the central nervous system through a series of events when an intracranial infection occurs. Intracranial infection has been treated in recent years by lumbar cistern drainage and broad-spectrum antimicrobial drugs. Vancomycin has been widely used in the treatment of intracranial infection ([@b6-etm-0-0-7503]) and is highly sensitive to Gram-positive bacteria, such as staphylococcus aureus and staphylococcus epidermidis. Meropenem is one of the semi-synthetic carbapenem antibacterial agents, the sensitivity of which to Gram-negative bacteria is up to 95%. The treatment safety and efficacy of intracranial infection has been confirmed ([@b7-etm-0-0-7503]). Intravenous injection is difficult to pass the blood-brain barrier, which results in severe intracranial infection, eventually causing the treatment to be more difficult with unsatisfactory effects. Therefore, other routes of administration are often selected clinically to reduce intravenous administration. Intrathecal injection is a treatment that is administered directly to the patient\'s CSF through lumbar puncture. Whether it can improve the efficacy and safety has also attracted the attention of scholars. In this study, the efficacy and safety of intrathecal meropenem and vancomycin in the treatment of postoperative intracranial infection in patients with STBI were investigated, in order to provide a reference for future clinical treatment.

Materials and methods
=====================

### General information

A retrospective analysis was performed on 86 patients with intracranial infections after cranial trauma operation in Tai\'an Traditional Chinese Medicine Hospital and Affiliated Hospital of Taishan Medical University (Tai\'an, China) from May 2004 to June 2017. The patients were divided into the control group (43 patients) and the experimental group (43 patients) according to the treatment. The experimental group consisted of 22 males and 21 females with an age range of 30.01±9.04 years. The control group consisted of 24 males and 19 females with an age range of 29.73±10.37 years. There were no statistically significant differences in the sex, age, body weight and cause of injury of patients between the two groups (P\>0.05), which were comparable ([Table I](#tI-etm-0-0-7503){ref-type="table"}).

### Methods

Patients in the two groups were routinely treated with antibiotics to prevent infection after craniotomy. After being diagnosed with intracranial infection, lumbar cistern drainage was performed on patients in the control group for the release of CSF, and then the patients were given vancomycin hydrochloride injection (Zhejiang Pharmaceutical Co., Ltd.; Xinchang Pharmaceutical Factory, Zhejiang, China; guoyaozhunzi: H20033366) 1.0 g, ivgtt, Q12H and intravenously dripped meropenem (Sumitomo Pharmaceutical Suzhou Co., Ltd., Suzhou, China; guoyaozhunzi: J20140169) 2.0 g, ivgtt, Q8H. Lumbar cistern drainage was performed on patients in the experimental group for the release of CSF, and then the patients were slowly given 20 mg of vancomycin hydrochloride injection. After the tube was flushed with 2 ml of 0.9% sodium chloride injection, the patients in the experimental group were given meropenem intrathecal injection 20 mg, bid. Patients in both groups were treated for 2 weeks.

### Inclusion and exclusion criteria

Inclusion criteria were: Patients who were diagnosed with STBI after admission; patients with Glasgow Coma Scale (GCS) scores between 3 and 8 points; patients with mydriasis. Exclusion criteria were: Patients with contraindications for vancomycin and meropenem; patients with uncertain conditions; patients with shock and fractures.

The study was approved by the Ethics Committee of Tai\'an Traditional Chinese Medicine Hospital and Affiliated Hospital of Taishan Medical University. Patients and their families were informed in advance of the study, and signed an informed consent form.

### Observation indicators and outcome measures

Observation indicators: The clinical efficacy, cure time, treatment cost, adverse reactions and sequelae after 6 months of treatment of patients in the two groups.

Outcome measures were: Recovered: Symptoms and signs disappeared and CSF examination was normal; markedly effective: the observation indicators were not fully recovered but the condition was improved; invalid: The condition deteriorated or was not improved after 72 h of treatment. Response rate (RR) = (number of recovered cases + number of markedly effective cases)/total number of cases ×100%.

### Statistical analysis

SPSS 17.0 (Beijing Boyi Zhixun Information Technology Co., Ltd., Beijing, China) software system was used for statistical analysis. Enumeration data were expressed as \[n (%)\], and χ^2^ test was used for comparison between the two groups. Students\' t-test was used for comparison between the two groups for continuous data. At P\<0.05, the difference was considered statistically significant.

Results
=======

### Clinical efficacy of patients in the two groups

There were 22 recovered patients, 19 markedly effective patients and 2 invalid patients in the experimental group, with an RR of 95.35%. There were 15 recovered patients, 16 markedly effective patients and 12 invalid patients in the control group, with an RR of 72.09%. The RR of patients in the experimental group was significantly higher than that in the control group, with a statistically significant difference (P\<0.05) ([Table II](#tII-etm-0-0-7503){ref-type="table"}).

### The cure time and treatment cost of patients in the two groups

The cure time and treatment cost of patients in the control group were 23±9 days and 2.6±1.2 yuan, respectively. Those of patients in the experimental group were 11±5 days and 1.8±0.7 yuan, respectively. The time to cure of patients in the experimental group was significantly shorter than that in the control group, with a statistically significant difference (t=7.643, P\<0.001). The treatment cost of patients in the experimental group was significantly lower than that in the control group, with a statistically significant difference (t=3.776, P\<0.001) ([Figs. 1](#f1-etm-0-0-7503){ref-type="fig"} and [2](#f2-etm-0-0-7503){ref-type="fig"}).

### Adverse reaction records of patients in the two groups

There was 1 patient with diarrhea, 1 patient with swelling and pain in the injection site and 1 patient with nausea in the experimental group, with an incidence of 6.98%. There were 2 patients with diarrhea, 4 patients with swelling and pain in the injection site and 4 patients with nausea in the control group, with the incidence of 23.26%. The incidence of adverse reactions of patients in the experimental group was significantly lower than that in the control group, with a statistically significant difference (P\<0.05) ([Table III](#tIII-etm-0-0-7503){ref-type="table"}).

### Sequelae of patients after 6 months of treatment in the two groups

After 6 months of treatment, there was no patient with auditory nerve abnormalities, 1 patient with motor nerve abnormalities and no patient with epilepsy in the experimental group, with the incidence of sequelae of 2.33%. There were 3 patients with auditory nerve abnormalities, 4 patients with motor nerve abnormalities and 2 patients with epilepsy in the control group, with the incidence of sequelae of 20.93%. The incidence of sequelae of patients in the experimental group was significantly lower than that in the control group, with a statistically significant difference (P\<0.05) ([Table IV](#tIV-etm-0-0-7503){ref-type="table"}).

Discussion
==========

TBI refers to a common trauma and is divided into light, moderate, heavy and extra-heavy traumas according to severity. Often accompanied by epilepsy, infection and cerebral infarction, which even causes coma in patients with serious TBI ([@b8-etm-0-0-7503],[@b9-etm-0-0-7503]). The mortality of TBI has been significantly reduced in recent years with the improvement of medical technology. However, due to the nerve function injury of patients, its disability rate remains high ([@b10-etm-0-0-7503],[@b11-etm-0-0-7503]). Patients with STBI are critically ill and often affected by increased intracranial pressure and toxic metabolites, resulting in sustained brain injury ([@b12-etm-0-0-7503],[@b13-etm-0-0-7503]). Intracranial infection, one of the complications of cranial operation, is treated with the complete elimination of surgical infected wounds, with antibiotic, symptomatic and supportive treatments ([@b14-etm-0-0-7503]). Intracranial infection usually occurs within 3--7 days after cranial operation ([@b15-etm-0-0-7503]), accompanied by fever, disturbance of consciousness and other clinical manifestations. Postoperative intracranial infection poses a serious threat to the patient\'s life and requires timely action ([@b16-etm-0-0-7503]). Intracranial infection refers to a disease caused by viruses and bacteria, especially for patients undergoing neurosurgery operation. It has a 10--25% infection rate, and a high mortality and disability rate ([@b17-etm-0-0-7503]--[@b19-etm-0-0-7503]). Therefore, optimizing STBI is of great significance. It is necessary to improve the prognosis of the patient, as well as reduce the cure time, hospitalization cost and incidence of complications in order to improve the quality of life and prognosis of the patient.

The efficacy was first compared in this experiment. The results showed that the RR of patients in the experimental group was significantly higher than that in the control group, with a statistically significant difference (P\<0.05). There is a study showing that ([@b20-etm-0-0-7503]) intravenous meropenem and vancomycin has a long cure time and high treatment cost, which also affects the liver and kidney function of the patient. At present, the use of intrathecal drugs has attracted much attention ([@b21-etm-0-0-7503]). Studies have confirmed ([@b22-etm-0-0-7503],[@b23-etm-0-0-7503]) that intrathecal vancomycin and meropenem has good clinical efficacy. This is similar to the results of this study. Then, the cure time and treatment cost of patients were compared between the two groups. The results showed that the cure time of patients in the experimental group was significantly lower than that in the control group, with a statistically significant difference (P\<0.001). The treatment cost of patients in the experimental group was significantly lower than that in the control group, with a statistically significant difference (P\<0.001). A study shows that ([@b24-etm-0-0-7503]) intrathecal meropenem and vancomycin is more effective than intravenous meropenem and vancomycin in the treatment of postoperative infection, which shortens the treatment time and reduces the treatment cost. Next, the adverse reactions of patients in the two groups were compared. The results showed that the incidence of adverse reactions of patients in the experimental group was significantly lower than that in the control group, with a statistically significant difference (P\<0.05). Finally, the sequelae of patients after 6 months of treatment were compared. The results showed that the incidence of sequelae of patients in the experimental group was significantly lower than that in the control group, with a statistically significant difference (P\<0.05). There is a study suggesting ([@b25-etm-0-0-7503]) that continuous lumbar drainage allows the CSF to drain continuously and slowly through the drainage tube, as well as reduces pathogenic microorganisms and inflammatory factors in the subarachnoid space so as to replace the CSF. In addition, intrathecal administration through the lumbar cistern reduces the incidence of adverse reactions and complications. The present study is an excellent complement to the results of that paper.

The number of patients included in this study is not large enough for conclusive statistics, so certain limitations exist and further investigations are required.

In summary, intrathecal meropenem and vancomycin is more effective than intravenous injection in the treatment of intracranial infection after craniotomy. It can shorten the treatment time and reduce the treatment cost, and is safer and has less adverse reactions and fewer complications.
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###### 

General information of patients in the two groups \[n (%)\].

  Group                   Experimental group (n=43)   Control group (n=43)   χ^2^ test   P-value
  ----------------------- --------------------------- ---------------------- ----------- ---------
  Sex                                                                                    
    Male                  22 (51.16)                  24 (55.81)             0.187       0.666
    Female                21 (48.84)                  19 (44.19)                         
  Age (years)                                                                            
    \<30                  17 (39.53)                  16 (37.21)             0.049       0.825
    ≥30                   26 (60.47)                  27 (62.79)                         
  Body weight                                                                            
    \<55                  15 (34.88)                  13 (30.23)             0.212       0.645
    ≥55                   28 (65.12)                  30 (69.77)                         
  Cause of injury                                                                        
    Falling down          11 (25.58)                  9 (20.93)              1.408       0.704
    Traffic accident      8 (18.60)                   12 (27.91)                         
    Dropping              14 (32.56)                  11 (25.58)                         
    Industrial accident   10 (23.26)                  11 (25.58)                         

###### 

The clinical efficacy of patients in the two groups \[n (%)\].

  Group                       Recovered    Markedly effective   Invalid      RR
  --------------------------- ------------ -------------------- ------------ ------------
  Experimental group (n=43)   22 (51.16)   19 (44.19)           2 (4.65)     41 (95.35)
  Control group (n=43)        15 (34.88)   16 (37.21)           12 (27.91)   31 (72.09)
  χ^2^ test                   --           --                   --           8.532
  P-value                     --           --                   --           0.004

###### 

Adverse reaction records of patients in the two groups \[n (%)\].

  Group                       Diarrhea   Swelling and pain in the injection site   Nausea     Incidence
  --------------------------- ---------- ----------------------------------------- ---------- ------------
  Experimental group (n=43)   1 (2.33)   1 (2.33)                                  1 (2.33)   3 (6.98)
  Control group (n=43)        2 (4.65)   4 (9.30)                                  4 (9.30)   10 (23.26)
  χ^2^ test                   --         --                                        --         4.440
  P-value                     --         --                                        --         0.035

###### 

Sequelae of patients after 6 months of treatment in the two groups \[n (%)\].

  Group                       Auditory nerve abnormalities   Motor nerve abnormalities   Epilepsy   Total incidence
  --------------------------- ------------------------------ --------------------------- ---------- -----------------
  Experimental group (n=43)   0 (0)                          1 (2.33)                    0 (0)      1 (2.33)
  Control group (n=43)        3 (6.98)                       4 (9.30)                    2 (4.65)   9 (20.93)
  χ^2^ test                   --                             --                          --         7.242
  P-value                     --                             --                          --         0.007
